title: [Screening for colorectal cancer: a cost benefit analysis on a health prevention programme at the Boehringer Ingelheim Company].
abstract: OBJECTIVE
  In Germany, approximately 70.000 people are diagnosed with colorectal cancer every year. With early diagnosis the recovery rates are over 90 % and early intervention can significantly reduce the costs of medical treatment as well as the economic losses from worker productivity. We here present the organisational procedure for bowel cancer screening and have weighed the costs against benefits to employees, the company and the healthcare system. The screening costs are compared with economic benefits.
  
  
  METHODS
  The target group for the study consisted of all 11.536 employees at the company's site in Germany. Volunteers were given a standardized questionnaire about the risk factors for colorectal cancers and an immunological fecal occult blood test (IFOBT). If risk factors for development of colorectal cancer were present or if the test result was positive, a colonoscopy was recommended in accordance with DGVS guidelines (German Society of Digestive and Metabolic diseases).
  
  
  RESULTS
  A total of 4.287 employees (37.2 %) indicated an interest in undergoing screening; at the end of the period 3.958 complete datasets (2.296 men and 1.662 women, mean age 51.2 years) were available for evaluation. A colonoscopy was performed on 114 persons. Six cases of overt cancer were detected with three in the 36 - 50 age group and three in the 51 - 65 age group. Five of the six cases were stage T1 or T2. Adenomatous polyps were found and removed in 29 persons. The calculated cost benefit ratio was 1:2 for the company and 1:35 for the public health system.
  
  
  CONCLUSIONS
  Using the example of colorectal screening, this study represents a cost benefit analysis of this preventative health measure in a company environment. The results show that even while taking into account the financial and personal commitment required, the cost benefit ratio is positive both for the company and for the healthcare system.
authors.affiliation: Werksärztlicher Dienst Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim. Michael.schneider@boehringer-ingelheim.com
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.forename: H-J
authors.initials: HJ
authors.lastname: Häck
mesh_terms: D018256:Adenomatous Polyps / Q000191:economics / Q000473:pathology / Q000517:prevention & control / Q000601:surgery; D000328:Adult; D003111:Colonic Polyps / Q000191:economics / Q000473:pathology / Q000517:prevention & control / Q000601:surgery; D003113:Colonoscopy / Q000191:economics*; D015179:Colorectal Neoplasms / Q000191:economics* / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D003362:Cost-Benefit Analysis; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics*; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D009367:Neoplasm Staging; D009780:Occult Blood; D009786:Occupational Health Services / Q000191:economics*